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Abstract
Background: The 1a,25-dihydroxy-3-epi-vitamin-D3 (1a,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin
D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent
transcription regulator. In vivo action of 1a,25(OH)2-3-epi-D3 is tissue-specific and exhibits lowest calcemic effect compared
to that induced by 1a,25(OH)2D3. To further unveil the structural mechanism and structure-activity relationships of
1a,25(OH)2-3-epi-D3 and its receptor complex, we characterized some of its in vitro biological properties and solved its
crystal structure complexed with human VDR ligand-binding domain (LBD).
Methodology/Principal Findings: In the present study, we report the more effective synthesis with fewer steps that
provides higher yield of the 3-epimer of the 1a,25(OH)2D3. We solved the crystal structure of its complex with the human
VDR-LBD and found that this natural metabolite displays specific adaptation of the ligand-binding pocket, as the 3-epimer
maintains the number of hydrogen bonds by an alternative water-mediated interaction to compensate the abolished
interaction with Ser278. In addition, the biological activity of the 1a,25(OH)2-3-epi-D3 in primary human keratinocytes and
biochemical properties are comparable to 1a,25(OH)2D3.
Conclusions/Significance: The physiological role of this pathway as the specific biological action of the 3-epimer remains
unclear. However, its high metabolic stability together with its significant biologic activity makes this natural metabolite an
interesting ligand for clinical applications. Our new findings contribute to a better understanding at molecular level how
natural metabolites of 1a,25(OH)2D3 lead to significant activity in biological systems and we conclude that the C3-
epimerization pathway produces an active metabolite with similar biochemical and biological properties to those of the
1a,25(OH)2D3.
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Introduction
The 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3 or calcitriol),
is the most active form of vitamin D3 and mediates its
pleiotropic effects through VDR activation, which heterodi-
merizes with retinoid X receptor (RXR). VDR-induced
genomic action results in growth inhibition of lymphomas,
breast or prostate primary tumor cells, renal osteodystrophy,
osteoporosis, psoriasis or autoimmune diseases [1,2]. Conse-
quently, VDR is an exquisite therapeutic target to combat
human metabolic diseases and uncontrolled cell proliferation in
many tissues [3–5]. In addition 1a,25(OH)2D3 is a key regulator
of calcium and phosphate homeostasis and bone metabolism but
its intrinsic hypercalcemic effect prevents its use in therapeutical
applications [6].
1a,25(OH)2D3 is subjected to enzymatic inactivation via two
major pathways leading to C-24 and C-23 hydroxylated
metabolites in various tissues [7–17]. While the side chain
oxidation is a general pathway associated to inactivation, another
metabolite modified at the A-ring, the 1a,25(OH)2-3-epi-D3, has
been shown to retain significant biological activity compared to the
natural hormone [18,19]. The 1a,25(OH)2-3-epi-D3 was initially
identified in the culture of human neonatal keratinocytes [20,21].
Further in vivo studies have characterized the occurrence of a C-3
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metabolite was detected in serum of rats treated with pharmaco-
logical doses of 1a,25(OH)2D3, and may therefore play an important
physiological role by buffering the level of 1a,25(OH)2D3.I n
addition, significant accumulation of 1a,25(OH)2-3-epi-D3 was
observed in different human adenocarcinoma cell lines such as
colon-derived Caco-2 cells[23] or NCI-H441 pulmonary cells [24].
Moreover, 1a,25(OH)2-3-epi-D3 was readily quantified in bovine
parathyroid cells, [25] rat osteoblastic UMR 106 and Ros17/2.8 cells
[26].
The production of 1a,25(OH)2-3-epi-D3 is initiated via A-ring
C3-epimerization (Figure 1), where the C-3 hydroxyl moiety is
Figure 1. Proposed pathway of the 1a,25(OH)2-3-epi-D3 production [18]. The reaction is initiated via A-ring C3-epimerization, where the C-3
hydroxyl moiety is changed from b to its diastereomer a. Two distinct pathways may be employed by cells to generate 1a,25(OH)2-3-epi-D3. The first,
more likely used pathway, starts with dehydrogenation catalyzed by yet unidentified enzyme leading to a keto-intermediate, which is converted most
probably by the same enzyme to the final product 1a,25(OH)2-3-epi-D3. The second one uses dehydration and a subsequent hydroxylation at C-3 a
position.
doi:10.1371/journal.pone.0018124.g001
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responsible for the C3-epimerization have not been identified to
present date. It was also proposed by Reddy et al. that this pathway
might be used for metabolites that resist inactivation through C-24
oxidation [18] a phenomenon well characterized in the bile acid
metabolism where the reaction is catalyzed by bile acid
hydroxysteroid dehydrogenase [27]. This pathway plays also a
major role in the activation and/or inactivation of steroid
hormones such as androgens [28].
Despite a lower binding affinity than calcitriol, 1a,25(OH)2-3-
epi-D3 possess significant biological activity only in specific tissues
where it is produced [29]. The transcriptional response of the
1a,25(OH)2-3-epi-D3 compound varies for different VDR-regu-
lated genes in different tissues. For instance, it shows lower
activation of osteocalcin gene and lower HL60 differentiation [30]
but has almost equipotent activity to 1a,25(OH)2D3 in inhibiting
cellular proliferation in keratinocytes [19] and in suppressing
parathyroid secretion in bovine parathyroid cells [25]. These in
vitro properties associated with its low calcemic activity [31,32]
assign potential therapeutic interest to this compound.
To further unveil, the structural mechanism and structure-
activity relationships of 1a,25(OH)2-3-epi-D3/hVDR-LBD com-
plex, we describe a more effective synthetic route to the synthesis
of 1a,25(OH)2-3-epi-D3, some of its in vitro biological properties
and the crystal structure of its complex with hVDR LBD.
Results and Discussion
Synthesis of the 1a,25(OH)2-3-epi-D3
The synthesis of the target 1a,25(OH)2-3-epi-D3 (1, Scheme S1)
was first described by Okamura’s group at Riverside from (R)-
carvone using the dienyne approach (13 steps, 8.5%) [33]. We
describe here an efficient and alternative convergent synthesis of 1
from (S)-carvone (9 steps, 13%) that features a palladium catalyzed
tandem process that produces the vitamin D triene unit
stereoselectively in one pot by coupling enol triflate 3 (A-ring
fragment) with an alkenyl metal intermediate 2 (CD-side chain
fragment) [34]. For reproducibility reasons we employed Indium
intermediates (M=InR2) instead of Zinc intermediates [35–37].
Synthesis of the A-ring fragment 3
Our synthesis starts with commercial (S)-carvone (4, Scheme S2),
which was reduced under Luche conditions [38] to alcohol 5a and
its epimer 5b (9:1 ratio as determined by
1H-NMR). The mixture of
alcohols 5 was subjected to Sharpless epoxidation [39] to provide
the desired epoxyalcohol 6a (58% yield, two steps) and the starting
ketone 4 (28%). The formation of 4 can be explained by oxidation
of 5a through the corresponding chair-like equatorially oriented
vanadium ester intermediate. Tert-butyldimethylsilyl protection of
6a gave 6b in 96% yield. Side-chain degradation on 6b by
Daniewski’s method [40] afforded alcohol 7a (71%), which was
protected to 7b in the usual way (91%). Epoxide 7b was converted
in 77% yield to dibromide 8b by the two-stepsequence: 1) oxidative
cleavage with periodic acid; 2) Corey-Fuchs side-chain extension
[41]. Finally, consecutive treatment of 8b with lithium diisopropy-
lamide and n-butyllithium followed by trapping of the resulting
enolate with N-(5-Cl-2-pyridil)bis(triflate) gave the desired enol
triflate 3 in 76% yield [42].
Synthesis of the upper fragment 2 and
1a,25(OH)2-3-epi-D3 (1b)
Alkenyl bromide 10 was prepared from ketone 9 by a modified
[43] Trost procedure [44]. Treatment of a mixture of bromide 10
and indium trichloride with tert-butyllithium, and coupling of the
resulting indium intermediate 2a with enol triflate 3 in the
presence of catalytic amounts of (Ph3P)4Pd and (dppf)PdCl2, gave,
after desilylation, the desired metabolite 1b in 58% yield (Scheme
S3). The detailed synthesis is described in the Methods S1.
1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 show similar
properties in coactivator peptide recruitment
The human transcriptional intermediary factor TIF2 coactiva-
tor (NCOA2) has been shown to interact with VDR [45]. The
induced recruitment of TIF2 coactivator peptide bearing the 3rd
LXXLL motif to the hVDR LBD was monitored in the presence
of increasing concentrations of 1a,25(OH)2D3 or 1a,25(OH)2-3-
epi-D3 using the luminescent oxygen channeling assays [46]. Our
results show that EC50 value for both metabolites are in the lower
nanomolar range, 1.2 and 2.5 nM for 1a,25(OH)2D3 and
1a,25(OH)2-3-epi-D3, respectively (Figure 2A).
1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 induce expression
of vitamin D target genes in human breast cancer
(MCF-7) cells with similar potency
The transactivation potency of 1a,25(OH)2-3-epi-D3 has been
reported for several VDR target genes in different model cell lines
such as MG-63 or ROS17/2.8 osteosarcoma cells [24,30]. While
the transcriptional activity in MG-63 cells using a vitamin D-
responsive element (VDRE) from human osteocalcin (2848/+10) and
rat CYP24 (2291/+9) gene promoters was lower upon stimulation
with 1a,25(OH)2-3-epi-D3 compared to 1a,25(OH)2D3 [47], using
2xVDREs reporter from CYP24 gene promoter in human
melanoma G-361 cells comparable transcriptional activity was
observed [48]. Thisresponse is mainly achieved in cells in which the
1a,25(OH)2-3-epi-D3 metabolite is produced [29]. We monitored
the dose-dependent VDR induced transcriptional activity in human
breast cancer cells (MCF-7) cells transfected with human CYP24
promoter (2414 to 264) containing VDRE fused to reporter
luciferase gene (Figure 2B). Here, we show that 1a,25(OH)2-3-epi-D3
is slightlylesspotentthan 1a,25(OH)2D3 indirectingtransactivation
assay as the EC50 induced by 1a,25(OH)2-3-epi-D3 is twice higher
than that of 1a,25(OH)2D3 (5.9 nM vs 2.9 nM). Thisdifferenceis in
agreement with our results obtained from cell free coactivator
peptiderecruitment assays. Our transactivation assays show that the
dose-dependent comparison between the 1a,25(OH)2-3-epi-D3 and
1a,25(OH)2D3 reveals that at 50% of the dose-response, the
transcriptional activity of the 3-epimer is 65% of that obtained with
1a,25(OH)2D3. Statistical analysis revealed a significant correlation
between both the induced-coactivator recruitment and transactiva-
tion assays (Pearson r=0.961** and r=0.986**, respectively),
indicating the similarity in the course of the dose response curves
for both 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3. The reason for
the discrepancy from the previously reported lower transactivation
potential of 1a,25(OH)2-3-epi-D3 may have its origin in different
CYP24 promoter fragment used in our experiments. Although, the
EMSA assays with nuclear extracts and in vitro translated full length
VDR and RXR reported by Nakagawa et al. [47] showed decreased
DNA complex formation of VDR-RXR heterodimer in the
presence of 1a,25(OH)2-3-epi-D3 compared to 1a,25(OH)2D3,t h e
same authors showed using two-hybrid system that the strength of
VDR-RXR heterodimerization in presence of 10nM of the 3-
epimer is 40% compared to that observed for 1a,25(OH)2D3.
Cell specific effects of 1a,25(OH)2-3-epi-D3
The magnitude of 1a,25(OH)2-3-epi-D3-mediated specific
biological outcomes versus that induced by 1a,25(OH)2D3 is cell
line specific. As such, it is established based only on CD11b
Structure-Function Activity of 1a,25(OH)2-3-Epi-D3
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biologically less potent than 1a,25(OH)2D3 in the human leukemia
anti-proliferation and pro-differentiation cellular model (HL60),
compared to 1a,25(OH)2D3 [47]. We monitor the precise dose-
dependent study of 1a,25(OH)2-3-epi-D3 - directed HL60 cell
anti-proliferation and differentiation by live cell enumeration and
flow cytometry based on the expression of both CD11c and CD14
cell surface markers. In our experiments for both, 1a,25(OH)2D3
and 1a,25(OH)2-3-epi-D3, only the saturating 100 nM concentra-
tion of ligand reduced the numbers of HL60 cells (Figure S1 and
Methods S2). Although for 1a,25(OH)2-3-epi-D3 the related
percentage of single positive or double CD11c/CD14 sub-
populations was higher compared to that observed in control
incubations, it was markedly reduced compared to that induced
with 100 nM 1a,25(OH)2D3, consistent with the previous study
[47].
Further, we hypothesized about the absence of the 1a,25(OH)2-
3-epi-D3 signaling in HL60 cellular model and thus turned to
characterize some of the biological properties of 1a,25(OH)2-3-
epi-D3 in cells where it is produced [20,21]. We first determined
the kinetics of CYP27B1- and CYP24A1-catalyzed oxidation by
monitoring the major lipophilic metabolites arising from a single
pulse of
3H[26,27]-25(OH)D3 at physiological concentration
(20.6 nM). During the first two hours, we observed a rapid
appearance of 1a,25(OH)2D3, from which at a slower rate the 3-
epimer was irreversibly formed. In total, some 60 independent
incubation experiments were performed on the kinetics of
3H[26,27]-25(OH)D3 using primary keratinocytes from various
donors and skin sites. In all experiments, highly comparable time
course of 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 were recorded
with 3-epimer exceeding 1a,25(OH)2D3 after longer incubation as
shown in Figure 2C and in the detailed HPLC analysis in Figure
Figure 2. 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 show similar biological properties. (A) Coactivator peptide recruitment assay was
performed using AlphaScreen method in the presence of increasing concentrations of either 1a,25(OH)2D3 (green circles) or 1a,25(OH)2-3-epi-D3
(blue circles). The data represents two independent measurements in triplicates for which the mean and the S.D. of the mean was calculated. (B)
Transactivation assays were performed in human breast cancer cells MCF7 cells with subsequent treatments of the increasing concentrations of either
1a,25(OH)2D3 (green circles) or 1a,25(OH)2-3-epi-D3 (blue circles). For every triplicate the mean and the S.D. were calculated. (C) Metabolism of
3H-
25(OH)D3 in human keratinocytes. Kinetics of the primary metabolite 1a,25(OH)2D3 and its 3-epimer, is shown. The time point 5 h, where the
1a,25(OH)2-3-epi-D3 is the major metabolite is highlighted with red arrow. Confluent keratinocytes derived from lid skin were incubated in KGM
(0.06 mM calcium) with 20.6 nM
3H[26,27]-25(OH)D3 for the indicated time periods. CHCl3-extracts of the incubations were analyzed on Zorbax-Sil
and individual metabolites identified by matching with authentic reference compounds and quantified as described in Materials and Methods. Data
(6 SD) was calculated from duplicate experiment. (D) Anti-proliferative cellular effect of 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 in human
keratinocytes. Keratinocytes in serum-free KGM (0.06 mM calcium) were seeded into 96-well plates and 24 h later the indicated metabolites (range
0.1–100 nM). After further 24 h, 1 mCi
3H-thymidine was applied to each well and its incorporation determined as described in Methods. Data are
mean values (6 SD) from a representative experiment out of two independent studies, each done in triplicates. For all experiments Student’s
unpaired t-test was performed and p-values were calculated between values obtained for 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3 (* p,0.05,
** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0018124.g002
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steadily up to 5 h in rather high concentration in this tissue and
the fact that the primary genomic effects of hVDR ligands are
exerted in first hours suggested that primary keratinocytes may be
a good cellular model to investigate the anti-proliferative actions of
this metabolite. Therefore we determined the dose-dependent
anti-proliferative effects of 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-
D3 using
3H-thymidine incorporation assay (Figure 2D), and
found that the IC50 values for 1a,25(OH)2D3 and 1a,25(OH)2-3-
epi-D3 were highly similar (41.4 and 66.1 nM, respectively) with
no significant statistical difference (using unpaired t-test p=0.074).
In addition, we correlated the course of the anti-proliferation data
between the two epimers and find a strong correlation (Pearson
r=0.940**) between them indicating the similar anti-proliferative
activity for 1a,25(OH)2D3 and 1a,25(OH)2-3-epi-D3. The anti-
proliferative effects of the two metabolites are comparable and
they are in close agreement with our coactivator peptide
recruitment (Figure 2A) and reporter gene assays (Figure 2B).
Although in this assay we cannot totally exclude the possibility that
the potential cell type specific difference in the function of the two
natural ligands may be partly due to the accumulation of
1a,25(OH)2-3-epi-D3 in 1a,25(OH)2D3 treated cells with C3-
epimerization ability leading to additive effect, we consider this
accumulation process as a naturally occurring in vivo physiological
event when 1a,25(OH)2D3 is present in these cells.
Overall structure of the hVDR complexed to
1a,25(OH)2-3-epi-D3
The mechanistic action of analogues of 1a,25(OH)2D3 is
unveiled by the determination at high resolution of the crystal
structure of their complexes with the VDR LBD [49–53]. We
solved the crystal structure of the complex formed by 1a,25(OH)2-
3-epi-D3 with the hVDR LBD mutant previously used to solve the
structures of hVDR LBD in complexes with 1a,25(OH)2D3 or
several synthetic agonists [49–54]. The crystal was isomorphous
and the structure of hVDR LBD bound to 1a,25(OH)2-3-epi-D3
determined at a resolution of 1.9 A ˚ (PDB ID: 3A78). The
crystallographic data are summarized in Table S1. After
refinement of the protein alone, the map showed an unambiguous
electron density where to fit the ligand (Figure 3B). The complex
formed by the hVDR LBD bound to 1a,25(OH)2-3-epi-D3 adopts
the canonical active conformation as described in all previously
reported agonist-bound nuclear receptor LBDs (Figure 3A). The
conformation of the activation helix 12 is strictly maintained.
When compared to the structure of hVDR LBD-1a,25(OH)2D3
complex, the atomic coordinates of hVDR LBD bound to
1a,25(OH)2-3-epi-D3 show very small root-mean-square deviation
(RMSD) of 0.17 A ˚ for all 255 Ca atoms, reflecting its high
structural homology.
Conformation of the 3a-epimer in the ligand-binding
pocket of hVDR
The 1a,25(OH)2-3-epi-D3, is buried in the predominantly
hydrophobic ligand-binding pocket (LBP) of the VDR. The
conformation of the 3-epi-hydroxyl group does not modify the A-
ring chair conformation of the ligand. Furthermore the seco B-, C-,
D- rings, and the aliphatic side chain present conformations similar
to those observed with 1a,25(OH)2D3 (Figure 3B and C).
In the complexes of hVDR LBD bound to 1a,25(OH)2D3
versus 1a,25(OH)2-3-epi-D3, the distance between the C1-OH
and the C25-OH groups varies from 13.1 A ˚ to 12.7 A ˚ and
between the C3-OH and the C25-OH groups from 15.3 A ˚ to
16.0 A ˚, respectively. The adaptation of the hVDR’s LBP to
different ligands can be described with the differential changes in
the volumes of LBPs and bound ligands. In addition the parameter
representing the % of LBP filling with ligand can provide useful
information about the activity of ligand [55]. All these parameters
are summarized in Table 1. Although the two diastereomer have
the same molecular weight and differ only in the position of the
C3-OH group, the 1a,25(OH)2-3-epi-D3 takes a slightly more
compact conformation in the LBP. The graphical 0.2 A ˚ mesh
representation of the superimposed LPBs presented in Figure 4A
Figure 3. Overall structure of the VDR-1a,25(OH)2-3-epi-D3 and conformation of the bound ligand. (A) Superimposition of the hVDR
LBD– 1a,25(OH)2-3-epi-D3 (blue) and the hVDR LBD–1a,25(OH)2D3 (white). The ligands are shown in stick representation in blue for the 1a,25(OH)2-3-
epi-D3 and in green for the 1a,25(OH)2D3. (B) The 1a,25(OH)2-3-epi-D3 is shown in its Fo – Fc electron density omit map contoured at 3 s. The ligand
is shown in stick representation with carbon and oxygen atoms in blue and red, respectively. (C) Stereo view of the ligand 3D conformations of
1a,25(OH)2-3-epi-D3 (blue) and 1a,25(OH)2D3 (green) in their VDR ligand-binding pockets (LBP).
doi:10.1371/journal.pone.0018124.g003
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1a,25(OH)2D3 (in green) and the one enlarged in case of
1a,25(OH)2-3-epi-D3 bound hVDR LBP (in blue). This suggests
that the hydrophobic residues lining the LBP are closer to the 3-
epimer and may compensate for the canonical hydrogen bonds.
We observed a notable adaptation with the displacement of the
side chain of the residue Tyr147 by 2.0 A ˚ compared to the
1a,25(OH)2D3 bound complex and the reorientation of the
Glu277 side chain away from the 1a,25(OH)2-3-epi-D3 due to
the a-position of the C3-OH group (Figure 4B). These specific
rearrangements lead to a more compact conformation resulting in
a 5% decrease in the volume of the LBP compared to
1a,25(OH)2D3.
Specific interactions of the 1a,25(OH)2-3-epi-D3
The hydrophobic and electrostatic interactions between the
receptor and the ligand are similar between the two structures
except around the C3-OH group. While the C1-OH and C25-OH
display the canonical hydrogen bonds, the 3-epi-OH of
1a,25(OH)2-3-epi-D3 interacts through hydrogen bonding only
with Tyr143 instead of interacting with both Tyr143 and Ser278
(Figure 5). A significant feature of the 1a,25(OH)2-3-epi-D3 is the
compensation of the loss of interaction with Ser278 by a water-
mediated hydrogen bond with the water molecule H2O1 (W1 in
[50]). As such, the position of water H2O1 is moved 0.7 A ˚ towards
1a,25(OH)2-3-epi-D3, thereby facilitating the specific water-
mediated contacts. This water molecule is part of the network
connecting another water molecule H2O2 to Arg274. All these
water molecules are also present in the 1a,25(OH)2D3–hVDR
complex [50]. The C3-OH hydrogen bonds have longer distances
in the 3-epimer (3.0 A ˚ instead of 2.8 A ˚ with Tyr143 and 3.1 A ˚
with the water molecule instead of 2.9 A ˚ with Ser278). A study on
the mutations of the residues forming the hydrogen bonds with the
hydroxyl groups of 1a,25(OH)2-3-epi-D3 revealed that mutated
residues contacting the 3-hydroxyl group are the less affected in
term of activity. Mutation of Ser278 in Ala may result in a lower
binding affinity for 1a,25(OH)2D3 [56] while showing a similar
potency to activate the transcription [57,56]. Due to the shift of the
side chain of Tyr147, a hydrophobic interaction with this residue is
lost in the 3-epimer structure. These structural data agree well
with the lower binding affinity of this compound for VDR and to
its induced biological activity.
In conclusion, we described a more effective synthesis of the
highly stable 1a,25(OH)2-3-epi-D3, a natural metabolite. We have
Figure 4. Adaptability of the hVDR LBP upon 1a,25(OH)2-3-epi-D3 binding. (A) The adaptation of the LBP is depicted by mesh
representation of the superimposed LBP volumes calculated with Voidoo software. The green surface represent the LBP area where the 1a,25(OH)2D3
bound pocket is larger. The blue area represents similar increase but for 1a,25(OH)2-3-epi-D3 and the two main expanded regions are highlighted
with red circles. (B) Adaptation of the residues Tyr147 and Glu277 in the LBP of the 1a,25(OH)2-3-epi-D3 hVDR complex. The distances between the
ligand-specific positions of the residues are displayed in A ˚.
doi:10.1371/journal.pone.0018124.g004
Table 1. Volume of VDR ligands and their resulting LBPs.
Ligand Ligand volume [A ˚ 3] * Ligand volume [%]* LBP volume [A ˚ 3]** LBP volume [%]** Filling of the LBP with ligand [%]
1a,25(OH)2D3 416.56 100.00 667.13 100.00 62.44
1a,25(OH)2-3-epi-D3 407.65 97.86 633.75 95.00 64.32
The absolute values in A ˚3 as well as relative values in reference to those of 1a,25(OH)2D3 (100%) are indicated. From these values the percent filling of the LBP with
ligands was also calculated.
*and ** Connolly solvent accessible surfaces calculated by GRASP and Voidoo respectively The quality of the cubic grid spacing for the surface for both ligands and
LBP=0.5 A ˚.
doi:10.1371/journal.pone.0018124.t001
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1a,25(OH)2-3-epi-D3, which provides a mechanistic insight for the
specific recognition of the two naturally occurring 3-epimers by
hVDR. Indeed, the crystal structure reveals that the 3-epimer
metabolite maintains the number of H-bonds by an alternative
water-mediated interaction. In MCF-7 cells, the 1a,25(OH)2-3-
epi-D3 on CYP24 gene promoter retains significant transcriptional
activity. In addition, the anti-proliferative action of 1a,25(OH)2-3-
epi-D3 is cell specific and the IC50 values of 1a,25(OH)2D3 and
1a,25(OH)2-3-epi-D3 in primary keratinocytes are in the same
nanomolar range. Therefore, we conclude that the C3-epimeriza-
tion pathway produces an active metabolite with similar
biochemical and biological properties to those of the
1a,25(OH)2D3. The physiological role of this pathway as the
specific biological action of the 3-epimer remains unclear and
needs further investigation. However, its high metabolic stability
together with its significant biologic activity makes this natural
metabolite an interesting ligand for clinical applications. Further
study on its target specificity and selectivity is required to the
design of selective analogues. Our new findings contribute to a
better understanding at molecular level how natural metabolites of
1a,25(OH)2D3 lead to significant activity in biological systems.
Materials and Methods
Ligands
1a,25(OH)2D3 was purchased from Cayman Chemical (Tallinn,
Estonia) and the synthesis of 1a,25(OH)2-3-epi-D3 is described in
more details in the Methods S1. Additional ligands and reference
compounds are described in Methods S2. IUPAC rules were used
for the name of the compounds. In addition to NMR spectra
(summarized in Methods S1), HPLC analysis was used to
determine the purity (.95%) of the vitamin D analogues.
Protein expression vectors for transactivation assays
Full-length cDNAs for human VDR [58] was subcloned into the
T7/SV40 promoter-driven pSG5 expression vector (Stratagene,
Heidelberg, Germany) and full-length cDNAs for green fluores-
cent protein (GFP) [59] was subcloned into parent vector resulting
the pEGFP-C2 mammalian expression vector (Clontech Labora-
tories, Inc., USA).
Luciferase reporter gene construct
The fragment of the proximal promoter region (2414 to 264)
of the human CYP24A1 gene was fused with the thymidine kinase
promoter driving the firefly luciferase reporter gene [60].
Coactivator peptide recruitment assays
Biochemical interaction between human VDR-LBD and the
coactivator peptide in the presence of 1a,25(OH)2D3 or
1a,25(OH)2-3-epi-D3 was assayed using the AlphaScreen technol-
ogy. The assay was performed in white opaque 384-well microplate
(OptiPlate-384 Perkin Elmer) using a final volume of 15 ml
containing final concentrations of 100 nM E. coli-expressed
hexahistidine (6xHis)-tagged VDR-LBD protein, 20 nM of the
human TIF2-3 biotinylated peptide (Btn-QEPVSPKKKENALL-
RYLLDKDDTKD), and 10 mg/ml of both AlphaLISA Ni
2+-
chelate acceptor beads and (AL108C)and AlphaScreen streptavidin
coated donor beads (6760002S) in an assay buffer containing
Figure 5. Specific interactions of 1a,25(OH)2-3-epi-D3 in the LBP of the hVDR. The ligands and residues in the superimposed structures are
highlighted in color (1a,25(OH)2-3-epi-D3 in blue and in 1a,25(OH)2D3 green) and the important water molecules are represented with colored dots.
doi:10.1371/journal.pone.0018124.g005
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100 mg/ml bovine serum albumin. Different concentrations of
1a,25(OH)2D3 or 1a,25(OH)2-3-epi-D3 dissolved in DMSO
(maintained ata final concentrationof1%)wereaddedas indicated.
The experiment represents two independent measurements in
triplicates for, which the mean and the S.D. of the mean was
calculated.
Transient transfections and luciferase reporter gene
assays
MCF-7 cells were seeded into 24-well plates (100,000 cells/well)
and grown overnight in phenol red-free Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% charcoal-
stripped fetal bovine serum (FCS) and 0.6 mg/ml insulin. Plasmid
DNA containing liposomes were formed by incubating 40 ng of an
expression vector for hVDR, 100 ng of reporter plasmid and
10 ng pEGF-C2 with Fugene 6 (Roche Diagnostics, Switzerland)
transfection reagent according to the recommendation of the
manufacturer for 15 min at room temperature. After dilution with
500 ml of phenol red-free DMEM, the liposomes were added to
the cells. Phenol red-free DMEM supplemented with 500 mlo f
20% charcoal-stripped FCS was added 4 h after transfection, in
the presence of ligands or solvent. The cells were lysed 16 h after
the onset of stimulation using reporter gene lysis buffer (Roche
Diagnostics, Switzerland). The lysates were assayed for luciferase
activity as recommended by the supplier (Perkin-Elmer, The
Netherlands). The luciferase activities were normalized to GFP
expression. Data represent one triplicate for which the mean and
the S.D. of the mean was calculated.
Data analysis for dose response curves
A non-linear curve fit was performed for the AlphaScreen and
reporter gene assay experimental dose response data and from
sigmoidal dose response curve then the EC50 values for the
respective ligands were calculated using GraphPad Prism 4
(GraphPad Software Inc., San Diego, CA). The Student’s
unpaired t-test and Pearson correlation were performed with the
SPSS software (SPSS Inc., version 14.0, Chicago, IL, USA).
Keratinocyte cell cultures
Normal human keratinocytes were isolated from fresh adult skin
obtained from surgery and immediately transported to the
laboratory under sterile conditions. Isolation and culture under
serum-free conditions and without a feeder layer followed a
modified protocol as used by Bikle et al [11]. The isolated epidermis
was incubated in a 0.25% trypsin solution for 45 min at 37uC.
Thereafter, the cells were scraped off and put in 50 ml Hank’s
balanced salt solution (HBSS) containing 10% FCS to block further
trypsin digestionand centrifuged at 2000 rpm/2 min. The resulting
cell pellet was suspended in Keratinocyte Growth Medium (KGM,
Clonetics Corp., San Diego), a defined serum-free medium at low
(0.06 mM) calcium containing 0.1 ng/ml epidermal growth factor,
5 mg/ml insulin, 0.5 mg/ml hydrocortisone, bovine pituitary
extract, antibiotics (gentamycin, amphothericin) gave the primary
culture. After 24 h, the cells were incubated at 37uC in 95% air/5%
CO2 and the attached cells were washed and provided with fresh
KGM medium. The culture medium was changed every other day
and the cells were passaged when they reached 80–90% confluency
(usually 6–10 days after plating).
Incubations of primary keratinocytes with
3H-25(OH)D3
Confluent human keratinocytes in 1 ml KGM and in 6-well
plates were incubated in duplicates at 37uC with 20.6 nM
3H-
25(OH)D3 (around 600 000 dpm/ml) for 1–23 h. Incubations
were stopped with 1 ml methanol/well, the cells were scraped off,
transferred to a test tube together with the supernatant and two
washings (with 1 ml methanol and 0.8 ml water). Unmodified
3H-
25(OH)D3 and most of the products were totally extracted from
the combined solutions plus cell pellet according to the method of
Bligh and Dyer [61] by three subsequent extractions with 2, 1 and
1 ml volumes of CHCl3 at room temperature.
3H-activity in the
CHCl3-phase, in the water and total
3H-yield were determined.
The combined CHCl3 extracts were then evaporated under argon
at 35uC, the residues dissolved in 0.4 ml ethanol and an aliquot
(containing around 250 000 dpm
3H-activity) subjected to HPLC-
analysis (see Methods S2).
3H-Thymidine incorporation (anti-proliferation assay in
primary keratinocytes)
Keratinocytes (second passage) in 200 ml KGM (low calcium)
were plated in 96-well plates at an initial density of 10
4 cells/well,
kept 24 h at 37uC in an incubator with 95% air/5% CO2.
Thereafter, the test compounds 1,25(OH)2D3 or its 3-epimer were
added in 1 ml ethanol to give final concentrations ranging from 0
to 100 nM, each condition in triplicates. After further 24 h, 50 ml
3H-thymidine (1 mCi) were added and incubation continued for
additional 7 h. Then, incubations were stopped by cell harvesting
(Filtermate 196 Harvester, Packard-Canberra) and lysis: After
removing the supernatant (see below), the adherent cells were
released by 5 min treatment with 100 ml 0.125% trypsin in PBS at
37uC, harvested on a filterplate and washed 3 x with redistilled
water. After drying the plates, their bottoms were sealed with a
film and 50 ml scintillation cocktail (MicroScint O, Packard) were
added. The whole plates were sealed with Packard Cover Film and
3H-activity counted on a Microplate Scintillation Counter
(TopCount, Packard Canberra). To check whether proliferative
(
3H-thymidine incorporating) cells could have been shed off, the
supernatants were soaked through a 96-well filterplate (Unifilter
Plate GF/C) and 3 x washed with redistilled water: in all
conditions,
3H-activity was undetectable on these filterplates (in
order to roughly assess cell numbers and check for substance
related morphological changes/toxic effects, photographs were
taken prior to compound addition and immediately before
harvesting.) Data - used as means 6 SD – were normalized
(incorporated
3H-activity sample vs. blank) and analyzed using the
GRAFIT Erithacus 4.0.19 IC50 software.
Protein purification and Crystallization
Purification and crystallization of the hVDR LBD complexed
with 1a,25(OH)2-3-epi-D3 were performed as previously described
[49]. The LBD of the hVDR (residues 118-427 D166-216) was
cloned in pET-28b expression vector (Novagen) to obtain an N-
terminal 6xHis fusion protein and was overproduced in E. coli
BL21 (DE3) strain. Cells were grown in Luria Bertani medium and
subsequently incubated for 6 h at 20uC with 1 mM isopropyl thio-
b-D-galactoside. The protein purification included a metal affinity
chromatography step on a Co
2+-chelating resin (Clontech). The
6xHis tag was removed by thrombin digestion overnight at 4uC,
and the protein was further purified by gel filtration on a Superdex
S200 16/60. The sample buffer prior to protein concentration
contained 10 mM Tris, pH=7.5, 100 mM NaCl, and 10 mM
dithiothreitol. The protein was concentrated to 3.5 mg/ml and
incubated in the presence of a 1.5-fold molar excess of ligand. The
purity and homogeneity of the protein were assessed by SDS-
PAGE. The protein crystals were obtained at 4uC by vapor
diffusion method using crystals of hVDR LBD-1a,25(OH)2D3 as
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1.4 M ammonium sulfate pH=6.0.
X-Ray data collection and structure determination
The crystal was mounted in fiber loop and flash cooled in liquid
nitrogen after cryoprotection with a solution containing the reservoir
plus 30% glycerol and 2% polyethylene glycol 400. Data collection
from a single frozen crystal was performed at 100 K on the beamline
ID29 of the European Synchrotron Radiation Facility (Grenoble,
France). The crystal belongs to the orthorhombic space group
P212121 with one monomer per asymmetric unit. Data were
integrated and scaled using MOSFLM [62] (see statistics in Table
S1).A rigid body refinement was used withthe structure of the hVDR
LBD complexed to 1a,25(OH)2D3 as a starting model. Refinement
involved iterative cycles of manual building and refinement
calculations. The programs Refmac [63] and COOT [64] were
used throughout structure determination and refinement. The omit
mapfromthe refinedatomicmodelofhVDRLBDwasusedtofitthe
ligand to its electron density, shown in Figure 2A. Individual B-
atomic factors were refined isotropically. Solvent molecules were then
placed according to unassigned peaks in the difference Fourier map.
In the hVDR/1a,25(OH)2-3-epi-D3 complex, refined at 1.9 A ˚ with
no s cutoff, the final model consists of residues 118-423 (D166–216),
the ligand, two sulphate ions and 372 water molecules. According to
PROCHECK [65] 92.6% of peptide lies in most favored regions and
7.4% in additional allowed regions. Data are summarized in Table
S1. The volumes of the ligand-binding pockets and ligands were
calculated as previously reported [49].
Supporting Information
Figure S1 Biological properties of 1a,25(OH)2D3 and
1a,25(OH)2-3-epi-D3 in HL60 cellular model. (A)
1a,25(OH)2-3-epi-D3-mediated HL60 cell growth. 1a,25(OH)2D3
or 1a,25(OH)2-3-epi-D3-treated HL60 at 1 nM and 100 nM
concentrations are counted. Data are presented as mean6S.D. of
the mean (*, p,0.05; **, p,0.01; ***, p,0.001). (B) 1a,25(OH)2-3-
epi-D3-mediated HL60 cell differentiation into monocyte-like cells.
HL60 cells were treated with either ethanol or 1 nM and 100"nM
concentration of 1a,25(OH)2D3 or 1a,25(OH)2-3-epi-D3.C e l l sw e r e
labeled with PElabeled anti-human CD11c and FITC-labeled anti-
human CD14, and HL60 cell differentiation was estimated by the
double-positive CD11c/CD14 population. Data are representative of
three distinct experiments.
(PDF)
Figure S2 Dominant production of the 1a,25(OH)2-3-
epi-D3 in keratinocytes after 5 h. HPLC profile of the
CHCl3-extract from keratinocytes after 5 h incubation is shown.
The amount of 1a,25(OH)2-3-epi-D3 (blue star) is the highest from
all the metabolites detected with HPLC. The peak of
1a,25(OH)2D3 is highlighted with green star.
(PDF)
Table S1 Data collection and refinement statistics.
(PDF)
Methods S1 Synthesis.
(PDF)
Methods S2
(DOCX)
Scheme S1 Retrosynthesis of 1b.
(PDF)
Scheme S2 Synthesis of enol triflate 3. Si=TBS= Si(t-
Bu)(CH3)2.TBHP= t-BuOOH (a) NaBH4, CeCl3?7H2O, MeOH,
0uC, 30 min. (b) TBHP, VO(acac)2, PhH, reflux, 30 min. (c)
TBSCl, Im, DMF, rt, 12 h. (d) O3, MeOH-CH2Cl2, 278uC;
Ac2O, Et3N, DMAP, 235uCt o28uC, 2 h; NaOAc, MeOH,
37uC, 12 h, (e) H5IO6,E t 2O, rt, 2 h. (f) CBr4, Zn, Ph3P, CH2Cl2,
rt, 40 min. (g) LDA, THF, 278uC, 1 h; n-BuLi, 15 min; 5-Cl-
Py-2NTf2, 278uC to rt, 12 h.
(PDF)
Scheme S3 Synthesis of metabolite 1. TES =
Si(CH2CH3)3. (a) (Ph3PCH2Br)Br, KOt-Bu, toluene, 25uC to rt,
1 h, 80%. (b) TESCl, Im, DMAP, DMF, rt, 3 h, 91%. (c) InCl3, t-
BuLi, THF, 278uCt o0 uC, 2 h. (d) 3, (Ph3P)4Pd, Et3N, THF,
(dppf)PdCl2,0 uC to rt, 12 h. (e) HF?Py, Et3N, CH2Cl2,C H 3CN,
rt, 4 h, 58%.
(PDF)
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